China & Japan Peripheral Vascular Devices Market

The China peripheral vascular devices market is projected to reach USD 1.30 billion by 2031 from USD 0.92 billion in 2026, growing at a CAGR of 6.9% during the forecast period.

The Japan peripheral vascular devices market is projected to reach USD 1.24 billion by 2031 from USD 0.83 billion in 2026, growing at a CAGR of 8.1% during the forecast period.

To know about the assumptions considered for the study download the pdf brochure

The rise in the number of patients affected by peripheral artery disease (PAD), diabetes, hypertension, and cardiovascular diseases boosts the demand for minimally invasive vascular interventions. This increases the demand for the usage of angioplasty balloons, stents, atherectomy systems, and CTO devices. Furthermore, the adoption of image-guided interventions, next-generation drug-coated devices, and precision therapies is resulting in innovative possibilities in drug-eluting stents, re-entry devices, vascular closure devices, and high-precision guidewires and catheters. The focus on digital vascular healthcare, the integration of AI-based imaging solutions, and the adoption of real-time procedural navigation systems in markets is an added advantage to these existing market drivers. The strict adherence to the changes in the regulatory reform environment in the NMPA of China and the PMDA of Japan, the establishment of more facilities to support manufacturing in China, and the scaling up of cooperation between international device manufacturers, domestic med tech companies, and research networks drive the market.

Prominent players in the China & Japan peripheral vascular devices market are Terumo Corporation (Japan), Medtronic (Ireland), Boston Scientific Corporation (US), Abbott (US), MicroPort Scientific Corporation (China), W. L. Gore & Associates, Inc. (US), ASAHI INTECC CO., LTD. (Japan), Cook (US), Nipro (Japan), and B. Braun SE (Germany). These companies adopted organic and inorganic growth strategies, such as product developments, partnerships, and business expansions, to boost their market share and enhance diversification.

For instance, in January 2024, W. L. Gore & Associates, Inc. (US) announced FDA approval for a lower-profile GORE VIABAHN VBX Balloon Expandable Endoprosthesis, expanding treatment options for patients with complex vascular disease.

Terumo Corporation (Japan)

Terumo?‍?‌‍?‍‌?‍?‌‍?‍‌ Corporation is a medical technology player with a broad-ranging portfolio of cardiovascular and endovascular solutions. The company has three core business segments: Cardiac and Vascular, Blood and Cell Technologies, and Medical Care Solutions. The Cardiac and Vascular Company is at the heart of the company’s peripheral vascular business, offering interventional systems, such as guidewires, catheters, sheaths, stents, balloons, embolization devices, and intravascular imaging-related solutions for minimally invasive vascular procedures. While it is actively involved in Japan in promoting radial-to-peripheral (R2P) access, procedural safety, and clinical outcomes, it is simultaneously developing its factory, localization, and partnership activities in China. Due to its vast R&D resources, top-notch production, and strong hospital connections throughout Asia, it has a great competitive position as a major innovator and supplier in the peripheral vascular devices market in China and ?‍?‌‍?‍‌?‍?‌‍?‍‌Japan.

Medtronic?‍?‌‍?‍‌?‍?‌‍?‍‌ (Ireland)

Medtronic is a player in medical technology. The company is involved in the device, therapy, and service development, manufacturing, and marketing divisions. Clinically, it extends its reach in areas such as cardiovascular disease, neuroscience, diabetes, and surgical care. Four core segments, namely Cardiovascular, Medical Surgical, Neuroscience, and Diabetes, form the basis of its operations. Its Cardiovascular segment is the one that glances the most towards the peripheral vascular devices market. Through its Coronary & Peripheral Vascular division, it provides catheters, stents, guidewires, and other endovascular solutions, helping in the diagnosis and treatment of peripheral vascular diseases. It has a widespread influence. Its operations are spread across the US, Europe, and Japan, while its manufacturing and R&D facilities are in the US, China, Ireland, Germany, and Italy.

Market Ranking

The top five players in the China & Japan peripheral vascular devices market are Terumo Corporation (Japan), Medtronic (Ireland), Boston Scientific Corporation (US), Abbott (US), and MicroPort Scientific Corporation (China). Terumo Corporation is leading with its extensive product offerings in catheters, guidewires, sheaths, and endovascular devices that have gained considerable popularity at major hospitals in Japan and Asia. Medtronic is steadily gathering pace with its wide product offerings in peripheral stents, balloons, guidewires, and embolic protection devices supported by strong medical evidence at major advanced vascular centers. Boston Scientific Corporation is making its presence felt with high-quality drug-eluting stents, drug-eluting balloons, and advanced imaging-guided interventional devices for peripheral procedures. Abbott is strengthening their base with innovative vascular devices that incorporate next-generation stents and intravascular imaging devices for precision-guided procedures. MicroPort Scientific Corporation is leading the market in China with its peripheral stent platforms that utilize local production with competitive pricing at major hospitals.

Related Reports:

China & Japan Peripheral Vascular Devices Market by Type [Catheters (Guiding, Angiography), Inferior Vena Cava Filters (Retrievable, Permanent), Plaque Modification Devices (Atherectomy, Thrombectomy), Guidewires, Introducer Sheaths] - Forecast to 2031

Contact:
Mr. Rohan Salgarkar
MarketsandMarkets™ INC.
1615 South Congress Ave.
Suite 103, Delray Beach, FL 33445
USA : 1-888-600-6441
sales@marketsandmarkets.com